Targeted therapeutics in SLE: Emerging strategies to modulate the interferon pathway

Clinical and Translational Immunology

Volumn 5, Issue , 2016, Pages

  Oon, Shereen ^a,b,c   Wilson, Nicholas J ^d   Wicks, Ian ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d CSL LIMITED   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMG 811; ANIFROLUMAB; ASG 009; BETA INTERFERON; BIIB 059; BIOLOGICAL PRODUCT; CSL 362; DV 1179; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GSK 2586184; HORMONE; IMO 3100; IMO 8400; INTERFERON; IRS 954; JANUS KINASE; JNJ 473; NUCLEIC ACID; RONTALIZUMAB; RSLV 132; SIFALIMUMAB; ST 2825; STAT PROTEIN; TAU INTERFERON; TOFACITINIB; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENETOCLAX;

AUTOIMMUNITY; DRUG TARGETING; ENVIRONMENTAL FACTOR; GENETICS; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT INDICATION;

EID: 85048742182     PISSN: None     EISSN: 20500068     Source Type: Journal    
DOI: 10.1038/cti.2016.26     Document Type: Review

References (128)

1. Squatrito D, Emmi G, Silvestri E, Ciucciarelli L, D'Elios MM, Prisco D et al. Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside. Auto Immun Highlights 2014; 5: 33-45.
2. Gualtierottoi R, Biggioggero M, Penatti A, Meroni P. Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 2010; 10: 3-7.
3. Pisetsky DS, Ullal AJ. The blood nucleome in the pathogenesis of SLE. Autoimmun Rev 2010; 10: 35-37.
4. Bijl M, Reefman E, Horst G, Limburg PC, Kallenberg CGM. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis 2006; 65: 57-63.
5. Hermann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41: 1241-1250.
6. Hakkim A, Furnrohr B, Amann K. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci 2010; 107: 9813-9818.
7. Fransen J, van der Vlag J, Ruben J, Adema G, Berden J, Hilbrands L. The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther 2010; 12: 207.
8. Moulton V, Tsokos G. Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res Ther 2011; 13: 207.
9. Jenks S, Sanz I. Altered B cell signaling in human systemic lupus erythematosus. Autoimmun Rev 2009; 8: 209-213.
10. Grammer A, Lipsky P. B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 2003; 5: 822-827.
11. Liossis S, Kovacs, Dennis G, Kammer G, Tsokos G. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 1996; 98: 2549-2557.
12. Liu K, Mohan C. Altered B cell signaling in lupus. Autoimmun Rev 2009; 8: 214-218.
13. Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J, Miyagawa H et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 1065-1067.
14. Zhang J, Roschke V, Baker KP, Wang Z, Alarcón GS, Fessler BJ et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6-10.
15. Hagberg N, Ronnblom L. Systemic lupus erythematosus-a disease with a dysregulated type I interferon system. Scand J Immunol 2015; 82: 199-207.
16. Barcellos LF, May SL, Ramsay PP, Quach HL, Lane JA, Nititham J et al. High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions. PLoS Genet 2009; 5: e1000696.
17. Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol 2011; 127: 303-312.
18. Gladman D, Urowitz M, Rahman P, Ibañez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1955-1959.
19. Rovin B, Furie R, Latinis K, Looney R, Fervenza F, Sanchez-Guerrero J et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment and Rituximab study. Arthritis Rheum 2012; 64: 1215-1226.
20. Merrill J, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation in rituximab trial. Arthritis Rheum 2010; 62: 222-233.
21. Clowse MEB, Wallace DJ, Furie R, Petri M, Pike M, Leszczynski P et al. Efficacy and safety of epratuzumab in patients with moderate-to-severe systemic lupus erythematosus: results from two phase 3 randomized, placebo-controlled trials [abstract 4L]. Arthritis Rheumatol 2015; 67. Available from http://acrabstracts.org/abstract/efficacyand-safety-of-epratuzumab-in-patients-with-moderate-to-severe-systemic-lupus-erythematosus-results-from-two-phase-3-randomized-placebo-controlled-trials/. Accessed 28 March 2016.
22. Iseberg D, Urowitz M, Merrill JT, Hoffman R, Linnik M, Morgan-Cox M et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus (SLE): results from 2 phase 3, 52-week, multicenter, randomized, double-blind, placebo-controlled trials. Paper presented at: 2014 American College of Rheumatology Annual Meeting, Boston, USA [abstract L25]. Available from http://acrabstracts. org/abstract/efficacy-and-safety-of-subcutaneous-tabalumab-in-patients-with-systemic-lupus-erythematosus-sle-results-from-2-phase-3-52-week-multicenter-randomized-double-blind-placebo-controlled-trials/. Accessed 28 March 2016.
23. Iseberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of ataticept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis 2015; 74: 2006-2015.
24. Le Bon A, Durand V, Kamphuis E, Thompson C, Bulfone-Paus S, Rossmann C et al. Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol 2006; 176: 4682-4689.
25. Chan VS, Nie YJ, Shen N, Yan S, Mok MY, Lau CS. Distinct roles of myeloid and plasmacytoid dendritic cells in systemic lupus erythematosus. Autoimmun Rev 2012; 11: 890-897.
26. Bacher N, Raker V, Hofmann C, Graulich E, Schwenk M, Baumgrass R et al. Interferon-? suppresses cAMP to disarm human regulatory T cells. Cancer Res 2013; 73: 5647-5656.
27. Cucak H, Yrlid U, Reizis B, Kalinke U, Johansson-Lindbom B. Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. Immunity 2009; 31: 491-501.
28. Taolaymat A, Leventhel B, Sakarcan A, Kashima H, Monteiro C. Systemic lupus erythematosus in a child receiving long-term interferon therapy. J Pediatr 1992; 120: 429-432.
29. Schilling P, Kurazrock R, Kantarjian H, Gutterman J, Talpaz M. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 1991; 68: 1536-1537.
30. Ho V, McLean A, Terry S. Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C. J Clin Rheumatol 2008; 14: 166-168.
31. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-723.
32. Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005; 64: 1692-1697.
33. Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006; 3: e491.
34. Bronson P, Chaivorapol C, Ortmann W, Behrens T, Grahan R. The genetics of type I interferon in systemic lupus erythematosus. Curr Opin Immunol 2012; 24: 530-537.
35. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197: 777-788.
36. Agrawal H, Jacob N, Carreras E, Bajana S, Putterman C, Turner S. Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol 2009; 183: 6021-6029.
37. Liu Z, Bethunaickan R, Huang W, Lodhi U, Solano I, Madaio M. Interferon-alpha accelerates murine systemic lupus erythematosus in a T cell-dependent manner. Arthritis Rheum 2011; 63: 219-229.
38. Yao Y, Higgs BW, Morehouse C, de Los Reyes M, Trigona W, Brohawn P et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-alpha monoclonal antibody trials in systemic lupus erythematosus. Hum Genomics Proteomics 2009; 2009: 1-16.
39. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006; 54: 1906-1916.
40. Singh MK, Scott TF, LaFramboise WA, Hu FZ, Post JC, Ehrlich GD. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. J Neurol Sci 2007; 258: 52-59.
41. Chiche L, Jourde-Chiche N, Whalen E, Presnell S, Gersuk V, Dang K et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol 2014; 66: 1583-1595.
42. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003; 4: 177-186.
43. Slavikova M, Schmeisser H, Kontsekova E, Matei?ka F, Borecky L, Kontsek P. Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia. J Interferon Cytokine Res 2003; 23: 143-147.
44. Kalunian K, Merrill J, Maciuca R, McBride JM, Townsend M, Wei X et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb inteferon-?) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016; 75: 196-202.
45. Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei G et al. Safety and efficacy of sifalimumab, an anti-IFN-alpha monoclonal antibody, in a phase 2b study of moderate to severe systemic lupus erythematosus (SLE). Paper presented at: 2015 American College of Rheumatology Annual Meeting, San Francisco, USA [abstract L4]. Available from http://acrabstracts.org/abstract/safety-and-efficacy-of-sifalimumaban-anti-ifn-alpha-monoclonal-antibody-in-a-phase-2b-study-of-moderate-to-severe-systemic-lupus-erythematosus-sle/. Accessed 28 March 2016.
46. Furie R, Merrill JT, Werth VP, Khamashta M, Kalunian K, Brohawn P et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus (SLE) [abstract 3223]. Arthritis Rheumatol 2015; 67. Available from http://acrabstracts.org/abstract/anifrolumab-an-anti-interferon-alpha-receptor-monoclonal-antibody-in-moderate-to-severe-systemic-lupuserythematosus-sle/. Accessed 28 March 2016.
47. Morehouse C, Chang L, Wang L, Brohawn P, Ueda S, Ilei G et al. Target modulation of a type I interferon (IFN) gene signature with sifalimumab or anifrolumab in systemic lupus erythematosus (SLE) patients in two open label phase 2 Japanese trials. Paper presented at: 2014 American College of Rheumatology Annual Meeting, Boston, USA [abstract 719]. Available from http://acrabstracts.org/abstract/target-modulation-of-atype-i-interferon-ifn-gene-signature-with-sifalimumab-or-anifrolumab-in-systemiclupus-erythematosus-sle-patients-in-two-open-label-phase-2-japanese-trials/. Accessed 28 March 2016.
48. Tcherepanova M, Curtis M, Sale M, Miesowicz F, Nicolette C. Results of a randomized placebo controlled phase Ia study of AGS-009, a humanized anti-inferferon-alpha monoclonal antibody in subjects with systemic lupus erythematosus. Ann Rheum Dis 2013; 71: 537.
49. Ducreux J, Vandepapeliere P, Caolaone F, Roucairol C, Croughs T, Houssiau FA et al. IFN-alpha kinoid induces neutralizing anti-IFNalpha antibodies that decrease the expression of IFN-induced and B cell activation associated transcripts: analysis of extended follow-up data from the IFN-K phase I/II study. Clin Exp Rheumatol 2015; 33: S35.
50. Idera announces presentation of positive data from phase 2 trial of TLR 7 and 9 antagonist in patients with moderate-to-severe plaque psoriasis. Available from http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID= 1816887. Accessed 31 January 2016.
51. Welcher AA, Boedigheimer M, Kivitz AJ, Amoura Z, Buyon J, Rudinskaya et al. Blockade of interferon-gamma normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus. Arthritis Rheumatol 2015; 67: 2713-2722.
52. Gottschalk T, Tsantikos E, Hibbs M. Pathogenic inflammation and its therapeutic targeting in systemic lupus erythematosus. Front Immunol 2015; 6: 550.
53. Amezcua-Guerra LM, Ferrusquia-Toriz D, Castillo-Martinez D, Marquez-Velasco R, Chavez-Rueda AK, Bojalil R. Limited effectiveness for the therapeutic blockade of interferon alpha in systemic lupus erythematosus: a possible role for type III interferons. Rheumatology 2015; 54: 203-205.
54. Lin SC, Kuo CC, Tsao JT, Lin LJ. Profiling the expression of interleukin (IL)-28 and IL-28 receptor alpha in systemic lupus erythematosus patients. Eur J Clin Invest 2012; 42: 61-69.
55. Wu Q, Yang Q, Lourenco E, Sun H, Zhang Y. Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity. Arthritis Res Ther 2011; 13: R88.
56. Lauterbach H, Bathke B, Gilles S, Traidl-Hoffmann C, Luber CA, Fejer G et al. Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC. J Exp Med 2010; 207: 2703-2717.
57. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006; 80: 4501-4509.
58. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005; 23: 275-306.
59. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006; 25: 383-392.
60. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahsen F. Plasmocytoid dendritic cells (natural interferon-?/?-producing cells) accumulate in cutaneous lupus erythematous lesions. Am J Pathol 2001; 159: 237-243.
61. Cederblad B, Blomberg S, Vallin H, Perers A, Alm GV, Rönnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-? producing cells. J Autoimmun 1998; 11: 465-470.
62. Blomberg S, Eloranta ML, Magnusson M, Alm GV, Ronnblom L. Expression of the markers BDCA-2 and BDCA-4 and production of interferon-alpha by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2524-2532.
63. Miyashita A, Fukushima S, Makino T, Yoshino Y, Yamashita J, Honda N et al. Proportion of lymphocytic inflammation with CD123 positive cells in lupus erythematous profundus predict a clinical response to treatment. Acta Derm Venereol 2014; 94: 563-567.
64. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005; 115: 407-417.
65. Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011; 3: 73ra19.
66. Sisirak V, Ganguly D, Lewis KL, Couillault C, Tanaka L, Bolland S et al. Genetic evidence for the role of plasmacytoid dendritic cells in systemic lupus erythematosus. J Exp Med 2014; 211: 1969-1976.
67. Rowland SL, Riggs JM, Gilfillan S, Bugatti M, Vermi W, Kolbeck R et al. Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model. J Exp Med 2014; 211: 1977-1991.
68. Cisse B, Caton M, Lehner M, Maeda T, Scheu S, Locksley R et al. Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development. Cell 2008; 135: 37-48.
69. Morel L. Genetics of SLE: evidence from mouse models. Nat Rev Rheumatol 2010; 6: 348-357.
70. Davison LM, Jorgensen TN. Sialic acid-binding immunoglobulin-type lectin H-positive plasmacytoid dendritic cells drive spontaneous lupus-like disease development in B6. Nba2 mice. Arthritis Rheumatol 2015; 67: 1012-1022.
71. Pellerin A, Otero K, Czerkowicz JM, Kerns HM, Shapiro RI, Ranger AM et al. Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms. EMBO Mol Med 2015; 7: 464-476.
72. Zhan Y, Carrington EM, Ko HJ, Vikstrom IB, Oon S, Zhang JG et al. Bcl-2 antagonists kill plasmacytoid dendritic cells from lupus-prone mice and dampen interferon-alpha production. Arthritis Rheumatol 2015; 67: 797-808.
73. Oon S, Wilson NJ, Wicks IP. An anti CD123 monoclonal antibody (CSL362) depletes plasmacytoid dendritic cells and inhibits CpG upregulated IFN-alpha production and IFN-alpha inducible gene expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheumatol 2014; 66: S1242 [abstract 2842].
74. Lopez de Padilla CM, Niewold TB. The type I interferons: basic concepts and clinical relevance in immune-mediated inflammatory diseases. Gene 2016; 576: 14-21.
75. Kono DH, Haraldsson MK, Lawson BR, Pollard KM, Koh YT, Du X et al. Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proc Natl Acad Sci USA 2009; 106: 12061-12066.
76. Savarese E, Chae OW, Trowitzsch S, Weber G, Kastner B, Akira S et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 2006; 107: 3229-3234.
77. Sabry A, Sheashaa H, El-Husseini A, Mahmoud K, Eldahshan KF, George SK et al. Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine 2006; 35: 148-153.
78. Tsantikos E, Oracki SA, Quillici C, Anderson GP, Tarlinton DM, Hibbs ML. Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6. J Immunol 2010; 184: 1348-1360.
79. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Schlomchik MJ. Tolllike receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006; 25: 417-428.
80. Savarese E, Steinberg C, Pawar RD, Reindl W, Akira S, Anders HJ et al. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum 2008; 58: 1107-1115.
81. Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and-independent dendritic cell activation by chromatinimmunoglobulin G complexes. J Exp Med 2004; 199: 1631-1640.
82. Zorro S, Arias M, Rianõ F, Paris S, Ramírez LA, Uribe O et al. Response to ODN-CpG by B cells from patients with systemic lupus erythematosus correlates with disease activity. Lupus 2009; 18: 718-726.
83. Tran NL, Manzin-Lorenzi C, Santiago-Raber ML. Toll-like receptor 8 deletion accelerates autoimmunity in a mouse model of lupus through a Toll-like receptor 7-dependent mechanism. Immunology 2015; 145: 60-70.
84. Umiker BR, Andersson S, Fernandez L, Korgaokar P, Larbi A, Pilichowska M et al. Dosage of X-linked toll-like receptor 8 determines gender differences in the development of systemic lupus erythematosus. Eur J Immunol 2014; 44: 1503-1516.
85. Wu YW, Tang W, Zuo JP. Toll-like receptors: potential targets for lupus treatment. Acta Pharmacol Sin 2015; 36: 1395-1407.
86. Dynavax regains full rights to investigational TLR7/9 inhibitor DV1179 following expiration of collaboration with GSK 2014. Available from http://investors.dynavax. com/releasedetail.cfm?releaseid=885172. Accessed 3 February 2016.
87. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005; 202: 113-119.
88. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007; 37: 3582-3586.
89. Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010; 465: 937-941.
90. Jiang W, Bhagat L, Yu D, Kandimalla ER, Agrawal S. IMO-3100, an antagonist of Toll-like receptors 7 and 9, modulates gene expression and regulatory networks induced by ligands. J Immunol 2009; 182 (Meeting Abstracts 1): 48.25.
91. Zhu F, Jiang W, Dong Y, Kandimalla E, La Monica N, Agrawal S. IMO-8400, a novel TLR7, TLR8 and TLR9 antagonist, inhibits disease development in lupus-prone NZBW/F1 mice. J Immunol 2012; 188: 12.
92. Arcudi L. Idera pharmaceuticals announces completion of patient enrollment in phase 2 trial of IMO-3100 in patients with psoriasis. Available from http://ir.iderapharma. com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=1745127. Accessed 31 January 2016.
93. Masangkay EG. Idera reports top-line trial data for IMO-8400 in psoriasis. Available from http://www.clinicalleader.com/doc/idera-reports-top-line-trial-data-for-imo-inpsoriasis-0001. Accessed 31 January 2016.
94. Arcudi L. Idera announces presentation of positive data from phase 2 trial of TLR 7 and 9 antagonist in patients with moderate-severe plaque psoriasis 2013. Available from http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID= 1816887. Accessed 31 January 2016.
95. Lipford G, Forsbach A, Zepp C, Nguyen T, Weeratna R, McCluskie M et al. Selective toll-like receptor 7/8/9 antagonists for the oral treatment of autoimmune diseases. Paper presented at: 2007 American College of Rheumatology Annual Meeting, Boston, USA [abstract 1596]. Available from https://acr.confex.com/acr/2007/webprogram/Paper8044.html. Accessed 28 March 2016.
96. Loiarro M, Capolunghi F, Fantò N, Gallo G, Campo S, Arseni B et al. Pivotal advance: inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol 2007; 82: 801-810.
97. Capolunghi F, Rosado MM, Cascioli S, Girolami E, Bordasco S, Vivarelli M et al. Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients. Rheumatology 2010; 49: 2281-2289.
98. Shrivastav M, Niewold TB. Nucleic acid sensors and type I interferon production in systemic lupus erythematosus. Front Immunol 2013; 4: 319.
99. Funabiki M, Kato H, Miyachi Y, Toki H, Motegi H, Inoue M et al. Autoimmune disorders associated with gain of function of the intracellular sensor MDA5. Immunity 2014; 40: 199-212.
100. Molineros JE, Maiti AK, Sun C, Looger LL, Han S, Kim-Howard X et al. Admixture mapping in lupus identifies multiple functional variants within IFIH1 associated with apoptosis, inflammation, and autoantibody production. PLoS Genet 2013; 9: e1003222.
101. Pothlichet J, Niewold TB, Vitour D, Solhonne B, Crow MK, Si-Tahar M. A loss-offunction variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients. EMBO Mol Med 2011; 3: 142-152.
102. Rice GI, del Toro Duany Y, Jenkinson EM, Forte GM, Anderson BH, Ariaudo G et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet 2014; 46: 503-509.
103. Macanovic M. The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol 1996; 106: 243-252.
104. Davis JC. Recombinant human DNase I (rhDNase) in patients with lupus nephritis. Lupus 1999; 8: 68-76.
105. Sun X, Widerman A, Agrawal N, Teal T, Tanaka L, Hudkins K et al. Increased RNase expression reduces inflammation and prolongs survival in TLR7 transgenic mice. J Immunol 2013; 190: 2536-2543.
106. Resolve development programs. Available from http://www.resolvebio.com/rslv/index. php. Accessed 31 January 2016.
107. Markopoulou A, Kyttaris VC. Small molecules in the treatment of systemic lupus erythematosus. Clin Immunol 2013; 148: 359-368.
108. Burmester G, Bianco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013; 381: 451-460.
109. Bachelez H, van de Kerkhof P, Strohal R, Kubanov A, Valenzuela F, Lee J et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 2015; 386: 552-561.
110. Sandborn W, Ghosh S, Panes J, Vranic I, Su C, Rousell S et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367: 616-624.
111. Schwartz DM, Bonelli M, Gadina M, O'Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 2016; 12: 25-36.
112. Wang S, Yang N, Zhang L, Huang B, Tan H, Liang Y et al. Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice. Lupus 2010; 19: 1171-1180.
113. Lu LD, Stump KL, Wallace NH, Dobrzanski P, Serdikoff C, Gingrich DE et al. Depletion of autreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2. J Immunol 2011; 187: 3840-3853.
114. Tagoe C, Putterman C. JAK2 inhibition in murine systemic lupus erythematosus. Immunotherapy 2012; 4: 369-372.
115. Elewa E, Zakaria O, Mohamed E, Boghdadi G. The role of interleukins 4, 17 and interferon gamma as biomarkers in patients with Systemic Lupus Erythematosus and their correlation with disease activity. Egypt Rheumatol 2014; 36: 21-27.
116. Talaat RM, Mohamed SF, Bassyouni IH, Raouf AA. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity. Cytokine 2015; 72: 146-153.
117. Ramani K, Biswas PS. Interleukin 17 signaling drives Type I interferon induced proliferative crescentic glomerulonephritis in lupus-prone mice. Clin Immunol 2016; 162: 31-36.
118. Uppal SS, Hayat SJ, Raghupathy R. Efficacy and safety of infliximab in active SLE: a pilot study. Lupus 2009; 18: 690-697.
119. GSK halts anti-inflammatory collaboration with Galapagos. Available from http://www. genengnews.com/gen-news-highlights/gsk-halts-anti-inflammatory-collaboration-withgalapagos/81250210/. Accessed 31 January 2016.
120. van Vollenhoven RF, Layton M, Kahl L, Schifano L, Hachulla E, Machado D et al. DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184. Lupus 2015; 24: 648-649.
121. Rigel scuttles R333 after phase II flop. Available from http://www.genengnews.com/gen-news-highlights/rigel-scuttles-r333-after-phase-ii-flop/81249024/Accessed 31 January 2016.
122. Montealegre Sanchez GA. Lipodystrophy and elevated temperatures (CANDLE): clinical characterization and initial response to Janus kinase inhibition with baricitinib. Arthritis Rheum 2013; 65: S758-S759.
123. Liu Y. Activated STING in a vascular and pulmonary syndrome. N Engl J Med 2014; 371: 507-518.
124. Khodadadi L, Cheng Q, Alexander T, Sercan-Alp O, Klotsche J, Radbruch A. Bortezomib plus continuous B cell depletion results in sustained plasma cell depletion and amelioration of lupus nephritis in NZB/W F1 mice. PLoS One 2015; 10: e0135081.
125. Lin W, Seshasayee D, Lee W, Caplazi P, McVay S, Suto E. Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus. Arthritis Rheum 2015; 67: 215-224.
126. Baccala R, Gonzalez-Quintial R, Schreiber RD, Lawson BR, Kono DH, Theofilopoulos AN. Anti-IFN-alpha/beta receptor antibody treatment ameliorates disease in lupuspredisposed mice. J Immunol 2012; 189: 5976-5984.
127. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF et al. Targeting Bcl2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 2016; 374: 311-322.
128. Smith BD, Roboz GJ, Walter RB, Altman JK, Ferguson A, Curcio TJ et al. 120 first-in man, phase I study of CSL362 (anti-IL3R?/anti-CD123 monoclonal antibody) in patients with CD123+ acute myeloid leukemia (AML) in CR at high risk for early relapse. Blood 2014; 124: 120.